Johnson & Johnson announced the release of three-year data from its Phase 3 GALAXI 2 and GALAXI 3 clinical trials evaluating the efficacy of its drug candidate TREMFYA (guselkumab) for the treatment of Crohn's disease.
The trials assessed the safety and effectiveness of TREMFYA in patients with moderate to severe Crohn's disease. The data presented demonstrates the drug's efficacy and shows a consistent efficacy profile compared to the initial findings from the trials.
The announcement highlights the long-term data regarding the treatment of the condition.
